Endocrine Abstracts

Introduction: The incidence of previously unrecognized lesions within the pituitary has been studied by MRI. The data suggest that up to 10% of people have clinically unsuspected pituitary tumors, the majority being<10 mm. Currently, little information is available about the prevalence of incidentally-discovered sellar masses.Objective: To perform a clinical audit on pituitary incidentalomas in order to establish an appropriate clinical approach to t...

Acromegaly is caused by excessive growth hormone (GH) secretion from pituitary adenomas. Transphenoidal surgery is the first-choice treatment, but new drug therapies (e.g. somatostatin analogs, SSA) offer promising avenues for medical treatment. Complementary diagnostic tools may assist this strategy, helping to refine drug choice. Here, we investigate the associations between postsurgical radiological features and molecular phenotype of pituitary tumors from acromegalic patie...

TSH-secreting pituitary adenomas (thyrotropinomas or TSH-omas) are rare. At diagnosis, TSH-omas are frequently macroadenomas presenting with variable symptoms, and signs of hyperthyroidism. Somatostatin analogs (SSA) are a very efficient treatment to improve clinical signs in patients with TSH-omas, reducing hormone levels (90%) and causing tumor shrinkage (50%).Inhibitory effects of SSA are mediated by a family of five somatostatin receptor subtypes (sst1-5), with sst2 and ss...

Background: Conventional therapy for chronic hypoparathyroidism (cHP) is often unable to maintain stable normal serum calcium (Ca) levels for a full 24 h, to control symptoms, to prevent the detrimental long-term effects on the kidney and to preserve normal bone architecture. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide specifically designed to activate the R0 conformation of the PTH receptor 1, that results in a prolonged calcemic response and a sustai...

Background: Conventional therapy with oral calcium (Ca) and active vitamin D (vitD) supplementation for chronic hypoparathyroidism (cHP) can induce or aggravate hypercalciuria and may lead to detrimental long-term renal complications. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide with a short half-life designed to activate the R0 conformation of the PTH 1 receptor which produces a prolonged calcemic response. This phase 2a study examined the effects of e...

Introduction: The incidence of thyroid cancer (TC) is low, but rising over time. Some studies point to a possible increase in mortality rate (MR) from this cancer in certain areas of Spain and Andalusia. Our purpose was to analyse the TC mortality in Andalusia and study how it has changed in the last years. We also analysed differences by age, sex, and geographic area.Methods: All deaths from TC were collected between January 1, 1975 and December 1, 2011...

The somatostatin receptor 5 (sst5) and its truncated splicing variants (sst5TMD5, sst5TMD4) are considered putative biomarkers that can predict pharmacological response or aggressiveness in several endocrine-related pathologies, such as acromegaly. sst5 is encoded by a gene, SSTR5, that lacks introns within its coding sequence, and hence, the splicing variants identified are generated by non-canonical splicing events. However, the mechanisms underlying their genesis a...